

Article

Antimicrobial Resistance Trends in Healthcare-Associated Infections in Lahore: A Tertiary Care Perspective

Muhammad Abdullah¹, Anmol Iqbal¹, Ijaz Ahmad¹, Azka Mubeen¹, Sidra Iqbal¹, Faizan Hameed¹

¹ Department of Medical Lab Technology, Faculty of Allied Health Sciences, Superior University Lahore, Pakistan

Correspondence

azkamubeen786@gmail.com

Cite this Article

Received	2025-03-07
Revised	2025-04-27
Accepted	2025-04-29
Published	2025-04-30
Authors' Contributions	MA, AI, IA contributed to concept and data collection; AM, SI to design and analysis; FH, AM drafted the manuscript.
Conflict of Interest	None declared
Data/supplements	Available on request.
Funding	None
Ethical Approval	Respective Ethical Review Board
Informed Consent	Obtained from all participants
Study Registration	-
Acknowledgments	N/A
Disclaimer: The views and data in articles are solely the authors'; the journal is not liable for their use.	
© 2025 by the Authors. This is an Open Access double blind peer reviewed publication licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0)	

ABSTRACT

Background: Antimicrobial resistance (AMR) is a critical global health concern, particularly in healthcare-associated infections (HCAs) where multidrug-resistant (MDR) pathogens compromise treatment efficacy and increase mortality. Tertiary care hospitals in low-resource settings like Lahore face growing threats due to poor antimicrobial stewardship, limited surveillance, and the emergence of resistance to last-line antibiotics. **Objective:** This study aimed to assess the prevalence, resistance profiles, and molecular mechanisms of AMR in HCAI pathogens in tertiary care hospitals in Lahore, focusing on high-risk Gram-negative organisms and their clinical impact in ICU settings. **Methods:** A retrospective observational study was conducted via systematic review of 53 peer-reviewed articles and regional surveillance reports published between 2014 and 2023. Inclusion criteria included studies from Lahore reporting resistance profiles of nosocomial pathogens; community-acquired infections and non-English sources were excluded. Data were extracted on pathogen distribution, resistance rates, and associated risk factors. Ethical compliance with the Declaration of Helsinki was ensured through exclusive use of anonymized, published data. Descriptive statistics were computed using SPSS v27. **Results:** E. coli (24%), Acinetobacter spp. (23%), and P. aeruginosa (19%) were the most prevalent pathogens. Carbapenem resistance reached 98% in Acinetobacter and 89% in Pseudomonas, while colistin retained 93-100% activity. Extended hospital stays and prior antibiotic exposure were associated with 85.5% of MDR cases. Only 38.1% of hospitals adhered to stewardship guidelines. **Conclusion:** MDR pathogens in Lahore's tertiary care hospitals present a significant challenge to patient safety and treatment efficacy. Strengthening antimicrobial stewardship, infection control, and molecular surveillance is urgently needed to curb the clinical impact of AMR.

Keywords: Antimicrobial Resistance, Healthcare-Associated Infections, Multidrug-Resistant Organisms, Intensive Care Units, Carbapenem Resistance, Polymyxin Resistance, Infection Control.

INTRODUCTION

Antimicrobial resistance (AMR) has emerged as one of the most pressing global health threats of the 21st century, fundamentally challenging the efficacy of modern medicine. It occurs when microorganisms, particularly bacteria, evolve mechanisms to withstand previously effective antimicrobial treatments, rendering common infections increasingly difficult to treat (1). The World Health Organization has identified AMR among the top ten global health concerns, highlighting its rapidly escalating impact on morbidity, mortality, and healthcare costs (2). This crisis is exacerbated by the widespread misuse and overuse of antibiotics in both human and veterinary medicine, poor adherence to prescribing guidelines, and limited public awareness, all of which contribute to the selective pressure driving resistance (3). In developing countries such as Pakistan, the situation is particularly

acute due to fragile healthcare infrastructure, inadequate infection control, and weak regulatory oversight (4).

Healthcare-associated infections (HCAIs), defined as infections acquired during medical or surgical treatment and not present at the time of hospital admission, are among the most significant contributors to AMR's clinical burden (5). These infections are especially prevalent in intensive care units (ICUs), where patients are often immunocompromised and subjected to invasive procedures that increase susceptibility to opportunistic and drug-resistant pathogens (6). Global estimates suggest that the incidence of HCAIs in ICU settings may exceed 40% in high-income countries, with significantly higher rates in low- and middle-income countries (LMICs), including Pakistan (7). The prevalence of multidrug-resistant organisms (MDROs) and extensively drug-

resistant organisms (XDRs) in such settings has resulted in limited therapeutic options, prolonged hospitalization, elevated treatment costs, and increased mortality rates (8).

A particularly concerning dimension of HCAs is the dominance of ESKAPE pathogens—*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella* spp., *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* spp.—which are recognized for their virulence, persistence in hospital environments, and resistance to multiple antimicrobial classes (9). These pathogens have been identified as key drivers of nosocomial infections in Pakistani hospitals and have shown resistance to even last-resort antibiotics such as carbapenems and polymyxins (10). Mechanisms such as beta-lactamase production, efflux pumps, target site modification, and plasmid-mediated gene transfer are increasingly implicated in the survival and spread of these bacteria in healthcare settings (11). Moreover, regional data from Lahore indicate a disturbingly high prevalence of Gram-negative bacterial infections in tertiary care ICUs, particularly involving *Escherichia coli*, *Klebsiella pneumoniae*, *Acinetobacter* spp., and *Pseudomonas aeruginosa*, all of which exhibit resistance to critical antimicrobial agents (12). The *mcr-1* gene-mediated resistance to colistin and extensive production of extended-spectrum beta-lactamases (ESBLs) have been documented, raising alarm over therapeutic limitations (13).

Despite recognition of the issue, surveillance data in Pakistan remain fragmented and inconsistent, especially across provinces such as Baluchistan, leading to an incomplete understanding of resistance dynamics (14). Additionally, poor adherence to antimicrobial stewardship programs—reported in fewer than 40% of Lahore's hospitals—and indiscriminate empirical use of third-generation cephalosporins have further compounded the problem (15). Ethical concerns also arise from insufficient infection control measures, unstandardized prescribing practices, and a lack of transparency regarding antibiotic use policies in many healthcare facilities. These institutional gaps not only facilitate the propagation of resistance but also threaten the broader public health ecosystem, as resistant organisms may spread into communities through patients discharged from hospitals or improper disposal of medical waste (16).

The One Health approach—emphasizing the interconnectedness of human, animal, and environmental health—has gained global recognition as a framework for addressing AMR comprehensively. However, its implementation in Pakistan remains limited, often constrained by systemic inefficiencies and a lack of cross-sector collaboration (17). There is an urgent need for multidisciplinary interventions that strengthen local antimicrobial surveillance, standardize infection control protocols, and promote judicious antibiotic prescribing based on susceptibility data. Existing literature underscores the severity of AMR among hospital-acquired infections in Lahore, yet a consolidated regional analysis focusing on tertiary care facilities, especially ICUs, remains lacking (18). This knowledge gap hinders the development of evidence-based policies and intervention strategies tailored to the Pakistani healthcare context.

This study aims to address this critical gap by reviewing the trends and mechanisms of antimicrobial resistance in healthcare-

associated infections within tertiary care hospitals of Lahore. Specifically, it seeks to analyze resistance profiles of major pathogens, examine risk factors linked to the emergence of multidrug resistance, and evaluate the role of stewardship and surveillance practices. By synthesizing available evidence, this research contributes to the national and international discourse on AMR and supports the formulation of targeted interventions suited to high-risk hospital environments in resource-constrained settings (19).

MATERIALS AND METHODS

The present study employed a retrospective observational design, aiming to analyze antimicrobial resistance (AMR) patterns in healthcare-associated infections (HCAs) within tertiary care hospitals in Lahore, Pakistan. The analysis focused on previously published literature, hospital surveillance reports, and antimicrobial susceptibility data collected from peer-reviewed regional studies conducted between 2014 and 2023. Because this was a secondary data-based review, no individual patient recruitment was conducted, and thus informed consent was not applicable. The included studies were selected based on the following criteria: peer-reviewed articles published in English, with data specific to tertiary care hospitals in Lahore and including antimicrobial susceptibility profiles of nosocomial pathogens. Studies were excluded if they lacked pathogen-specific resistance data, were focused on community-acquired infections, or did not originate from Lahore-based hospital settings.

Data collection involved a systematic review of antimicrobial susceptibility testing (AST) results reported in the included studies. The primary outcomes assessed were prevalence rates of multidrug-resistant organisms (MDROs) among common HAI pathogens and their resistance profiles against major antibiotic classes, including carbapenems, cephalosporins, fluoroquinolones, aminoglycosides, and polymyxins. Secondary outcomes included the identification of key resistance mechanisms, such as extended-spectrum beta-lactamase (ESBL) production, carbapenemase expression, efflux pump activation, and plasmid-mediated resistance genes like *mcr-1* and *bla_{NDM}*. Data were extracted on pathogen distribution (e.g., *Escherichia coli*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and MRSA), rates of resistance to specific antibiotics, and associated clinical and epidemiological factors such as ICU stay duration, device use, and empirical antibiotic therapy. The studies reviewed used standardized AST methods, including disk diffusion and minimum inhibitory concentration (MIC) testing, interpreted according to Clinical and Laboratory Standards Institute (CLSI) guidelines, although methodology may have varied slightly across hospitals.

This literature-based review did not involve new data collection from human subjects. However, all original studies included in the analysis were reviewed to confirm their adherence to ethical standards. The synthesis of findings was conducted in compliance with the Declaration of Helsinki, and the confidentiality of data was ensured by relying exclusively on aggregated and anonymized published results.

Statistical analysis was performed using IBM SPSS Statistics version 27. Descriptive statistics, such as means and percentages,

were used to summarize pathogen prevalence and antibiotic resistance patterns. Comparative assessments were made between the resistance rates reported across different hospitals and years to identify trends and variations. Where possible, cross-study consistency was assessed to validate findings. Due to the nature of the review, no patient-level data or missing data imputation was required. Confounding variables such as hospital-specific infection control protocols and differences in stewardship implementation were noted qualitatively and considered when interpreting resistance trends (36).

RESULTS

A total of 82.2% of healthcare-associated infection (HAI) isolates reported in tertiary care hospitals in Lahore were Gram-negative bacteria, while Gram-positive organisms constituted a smaller fraction of infections. Among Gram-negative pathogens, *Escherichia coli* (24%), *Acinetobacter* spp. (23%), *Pseudomonas aeruginosa* (19%), and *Klebsiella pneumoniae* (13%) were the most prevalent. Methicillin-resistant *Staphylococcus aureus* (MRSA) accounted for 11% of Gram-positive isolates. High resistance levels were observed across all major pathogens to first-line antibiotics, particularly among Gram-negative organisms, which demonstrated extensive drug resistance patterns.

Table 1. Resistance Profiles and Mechanisms of Major HAI Pathogens in Lahore

Pathogen	Resistance Profile	Key Resistance Mechanisms
<i>Acinetobacter baumannii</i>	98% carbapenem resistance; 94–98% cephalosporin resistance	MBL, ESBL production
<i>Pseudomonas aeruginosa</i>	89% carbapenem resistance; 92.9% ciprofloxacin resistance	Efflux pumps, β -lactamase genes
<i>Escherichia coli</i>	100% resistance to ceftazidime and ampicillin	ESBL, <i>mcr-1</i> gene (colistin resistance)
MRSA	100% resistance to β -lactams; emerging vancomycin resistance	<i>mecA</i> gene, altered PBPs

Resistance to carbapenems was highest in *Acinetobacter baumannii* (98%) and *P. aeruginosa* (89%). Resistance in *E. coli* and *Klebsiella pneumoniae* remained relatively lower, with 68–72% susceptibility to carbapenems. Colistin retained high efficacy

across Gram-negative isolates, with 100% susceptibility in *Acinetobacter* and 86–93% in *Klebsiella* and *Pseudomonas*, although plasmid-mediated *mcr-1* gene presence in *E. coli* remains a significant emerging threat.

Table 2. Prevalence and Antibiotic Susceptibility of Major Pathogens in HAIs

Pathogen	Prevalence (%)	High-Resistance Antibiotics	Susceptibility to Last-Line Agents
<i>Escherichia coli</i>	24	Ceftazidime (100%), Ampicillin (100%)	Meropenem (71%), Imipenem (63%)
<i>Acinetobacter</i> spp.	23	Cephalosporins (94–98%), Carbapenems (98%)	Colistin (100%)
<i>Pseudomonas aeruginosa</i>	19	Ciprofloxacin (92.9%), Carbapenems (89%)	Colistin (93%), Amikacin (52%)
<i>Klebsiella pneumoniae</i>	13	Ampicillin (0%), Co-trimoxazole (0%)	Imipenem (60%), Colistin (86%)
MRSA	11	Penicillin (1.1%), Ceftazidime (0%)	Vancomycin (100%), Linezolid (98%)

Extended-spectrum β -lactamase (ESBL) production was a predominant resistance mechanism in *E. coli*, particularly among urinary tract infections (70.8% prevalence in UTI cases). Carbapenem resistance in *Acinetobacter* spp. and *P. aeruginosa* was primarily driven by efflux mechanisms and β -lactamase gene overexpression. Carbapenems displayed variable efficacy across Gram-negative pathogens. While susceptibility remained

moderate in *Klebsiella pneumoniae* (60%) and *E. coli* (71%), it was markedly reduced in *Acinetobacter* (21%) and *Pseudomonas* (52%). Aminoglycosides offered slightly better efficacy, with *E. coli* showing 78% susceptibility and *Klebsiella* 50%, though *Acinetobacter* (31%) and *Pseudomonas* (52%) exhibited considerable resistance. All tested isolates were resistant to third-generation cephalosporins.

Table 3. Comparative Efficacy of Antibiotic Classes Against Gram-Negative Pathogens

Antibiotic Class	<i>E. coli</i>	<i>Acinetobacter</i>	<i>P. aeruginosa</i>	<i>Klebsiella</i>
Carbapenems	71%	21%	52%	60%
Aminoglycosides	78%	31%	52%	50%
Polymyxins (e.g., colistin)	100%	100%	93%	86%
3rd-gen Cephalosporins	0%	0%	0%	0%

Among clinical risk factors, prolonged hospitalization (≥ 5 days) and invasive medical devices (e.g., urinary catheters, ventilators) were significantly associated with multidrug-resistant infections, contributing to 85.5% of MDR cases. Prior exposure to antibiotics was documented in 71.5% of these cases, highlighting poor stewardship compliance. Furthermore, third-generation cephalosporins were used empirically in 38.5% of isolates, despite over 90% resistance among Gram-negative strains, raising

concern for inappropriate empirical therapy. Surgical prophylaxis accounted for 33% of total antibiotic use, often exceeding recommended durations and potentially contributing to selective resistance pressures.

Surveillance data analysis revealed geographical imbalances, with Punjab and Sindh contributing 35.48% and 40.86% of national antimicrobial resistance (AMR) reporting, respectively. Baluchistan remained significantly underrepresented in national

AMR data. Additionally, only 38.1% of tertiary care hospitals in Lahore were found to comply with antimicrobial stewardship guidelines, suggesting variable adherence and underreporting, which may distort local resistance trends.

Collectively, these results highlight the critical role of Gram-negative pathogens in driving resistance in healthcare settings and emphasize the need for improved stewardship practices and surveillance infrastructure. The consistently high resistance to β -lactams and cephalosporins across all studied pathogens and the emerging resistance to polymyxins underscore the urgency of deploying evidence-based interventions in Lahore's tertiary healthcare institutions.

DISCUSSION

The findings of this study underscore a growing crisis of antimicrobial resistance (AMR) in healthcare-associated infections (HAIs) within tertiary care hospitals in Lahore, with Gram-negative pathogens exhibiting particularly alarming resistance profiles. These results are consistent with global and regional trends, where multidrug-resistant (MDR) organisms have become entrenched in high-risk clinical environments such as intensive care units (ICUs)(1). The predominance of pathogens like *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii* in HAI isolates, combined with their resistance to frontline therapies including third-generation cephalosporins and carbapenems, reaffirms the critical nature of AMR in nosocomial settings. Such findings parallel earlier studies conducted across South Asia, where *Acinetobacter* and *Klebsiella* spp. have emerged as key drivers of XDR infections, posing therapeutic challenges due to limited treatment options (10, 24).

Resistance mechanisms observed in this review, such as extended-spectrum β -lactamase (ESBL) and carbapenemase production, overexpression of efflux pumps, and plasmid-mediated genes like *mcr-1*, have been widely documented in recent literature as major contributors to the resistance phenotype in Gram-negative bacteria (11, 43). The widespread resistance to β -lactams and fluoroquinolones, and emerging resistance to last-resort agents such as polymyxins, indicate both intrinsic adaptability and extensive horizontal gene transfer among pathogens in hospital environments. The identification of colistin resistance, particularly in *E. coli*, through plasmid-mediated *mcr* genes raises serious clinical concerns, given colistin's role as a salvage therapy for XDR infections (52). These molecular findings corroborate previous surveillance efforts in Pakistan and align with WHO warnings about the escalating threat posed by mobile resistance determinants (9, 54).

Clinically, the implications are profound. High rates of resistance to empirical treatments—particularly third-generation cephalosporins and carbapenems—may lead to increased reliance on combination therapies or more toxic alternatives, potentially elevating the risk of adverse drug events, lengthened hospital stays, and elevated mortality rates. The strong association of MDR infections with prolonged hospitalization and invasive medical devices observed in this review supports earlier observations from Latin America and Southeast Asia, which have identified similar risk patterns in ICU patients (25, 36). Empirical overuse of

antibiotics, notably cephalosporins, despite high resistance prevalence, reflects poor adherence to stewardship protocols and highlights the need for evidence-based prescribing guided by antimicrobial susceptibility testing.

Comparatively, this study advances the field by offering a consolidated regional perspective specific to Lahore, addressing a critical gap in local surveillance data. While several national reports have described AMR trends in Pakistan, few have focused exclusively on tertiary care hospitals or disaggregated data at the city level, thereby overlooking important epidemiological nuances (36, 44). The finding that only 38.1% of Lahore's hospitals comply with antimicrobial guidelines is both alarming and indicative of systemic barriers to effective stewardship. This observation aligns with earlier studies emphasizing limited regulatory enforcement and uneven implementation of infection control protocols in public and private sector hospitals across Pakistan (38, 41).

The results also highlight a critical imbalance in national AMR reporting, with Punjab and Sindh dominating the data landscape while provinces like Baluchistan remain underrepresented. This regional disparity hampers national planning and obscures the true geographic spread of resistance. Although this review is strengthened by its comprehensive synthesis of peer-reviewed data spanning nearly a decade, it also faces limitations. As a literature-based review, it is inherently dependent on the methodological rigor and reporting transparency of the included studies. Heterogeneity in antimicrobial susceptibility testing methods, lack of standardized definitions across hospitals, and inconsistent reporting formats limit the ability to conduct meta-analytic assessments or draw robust statistical inferences.

Furthermore, the exclusion of non-English literature and unpublished surveillance data may result in selection bias, and the findings cannot be generalized beyond the tertiary care context without caution. Another limitation is the lack of patient-level data, which precludes analysis of clinical outcomes such as treatment failure, duration of hospitalization, and mortality associated with MDR infections. Nonetheless, the study provides essential insight into local resistance dynamics and can serve as a foundation for targeted interventions.

Future research should prioritize real-time surveillance systems, the molecular characterization of resistance genes using whole-genome sequencing, and the evaluation of stewardship interventions through prospective cohort studies. Strengthening laboratory capacity, improving infection control infrastructure, and integrating antimicrobial stewardship into clinical decision-making are urgently needed steps. Collaborative initiatives between policymakers, clinicians, microbiologists, and public health professionals will be crucial to curb the trajectory of AMR in Pakistan. By addressing the multifaceted drivers of resistance and enhancing the granularity of local data, health systems can better align clinical practices with the emerging realities of antibiotic resistance. This study contributes to that objective by delineating the patterns, drivers, and implications of AMR in Lahore's tertiary care hospitals, thus laying the groundwork for sustainable policy and clinical reform.

CONCLUSION

This review highlights the alarming rise of antimicrobial resistance (AMR) in healthcare-associated infections (HCAIs) within tertiary care hospitals in Lahore, with Gram-negative pathogens such as *Escherichia coli*, *Acinetobacter baumannii*, and *Pseudomonas aeruginosa* exhibiting extensive resistance to critical antibiotic classes including carbapenems and third-generation cephalosporins. The dominance of ESKAPE pathogens and the emergence of plasmid-mediated resistance mechanisms, particularly to last-resort agents like colistin, underscore a critical threat to patient safety, especially in intensive care settings. These findings emphasize the urgent need for strengthened antimicrobial stewardship programs, standardized infection control protocols, and improved local surveillance to mitigate the spread of multidrug-resistant organisms. Clinically, the persistence of such resistance patterns compromises therapeutic efficacy and escalates healthcare burdens, while from a research perspective, the data call for molecular-level studies to track resistance gene dissemination and evaluate targeted interventions. This study reinforces the necessity of coordinated action at institutional and policy levels to address the escalating AMR crisis in tertiary care healthcare settings.

REFERENCES

- World Health Organization. Antimicrobial Resistance: Global Report on Surveillance 2014. Geneva: World Health Organization; 2014.
- Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE. Trends in Antimicrobial Resistance Among Major Pathogens in the United States. *Clin Infect Dis*. 2004;38(Suppl 4):S101-8.
- Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, et al. Antibiotic Resistance in India: Drivers and Opportunities for Action. *BMJ*. 2013;346:f3398.
- Alanis AJ. Resistance to Antibiotics: Are We in the Post-Antibiotic Era? *Arch Med Res*. 2005;36(6):697-705.
- Hawkey PM, Jones AM. The Changing Epidemiology of Resistance. *J Antimicrob Chemother*. 2009;64(Suppl 1):i3-10.
- Cosgrove SE. The Relationship Between Antimicrobial Resistance and Patient Outcomes: What Are the Data? *Clin Infect Dis*. 2006;42(Suppl 2):S82-9.
- Livermore DM. Multiple Mechanisms of Antimicrobial Resistance in *Pseudomonas Aeruginosa*: Our Worst Nightmare? *Clin Infect Dis*. 2002;34(5):634-40.
- Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-Resistant, Extensively Drug-Resistant and Pandrug-Resistant Bacteria: An International Expert Proposal for Interim Standard Definitions for Acquired Resistance. *Clin Microbiol Infect*. 2012;18(3):268-81.
- Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad Bugs, No Drugs: No ESKAPE! An Update From the Infectious Diseases Society of America. *Clin Infect Dis*. 2009;48(1):1-12.
- Paterson DL. Resistance in Gram-Negative Bacteria: Enterobacteriaceae. *Am J Med*. 2006;119(6 Suppl 1):S20-8.
- Livermore DM. Carbapenemases: The Creep of CRE. *Drug Resist Updat*. 2012;15(1-2):39-48.
- Dellit TH, Owens RC, McGowan JE, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship. *Clin Infect Dis*. 2007;44(2):159-77.
- Emami Meybodi MM, Mirmohammadkhani M, Sharifi Y, Fazel M, Mokhtari M, Khosravi A. Prevalence of Antimicrobial Resistance Among Hospital-Acquired Infections at Imam Khomeini Hospital Complex, Tehran, Iran. *Antimicrob Resist Infect Control*. 2019;8:172.
- Morehead MS, Scarbrough C. Antimicrobial Resistance in Surgical Site Infections: A Systematic Review. *Surg Infect (Larchmt)*. 2014;15(6):609-16.
- Okeke IN, Aboderin OA, Byarugaba DK, Ojo KK, Opintan JA. Antimicrobial Resistance in Developing Countries. Part I: Recent Trends and Current Status. *Lancet Infect Dis*. 2005;5(8):481-93.
- O'Neill J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. London: Review on Antimicrobial Resistance; 2016.
- Rice LB. Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE. *Clin Infect Dis*. 2008;47(7):939-41.
- Neu HC. The Crisis in Antibiotic Resistance. *Science*. 1992;257(5073):1064-73.
- Clatworthy AE, Pierson E, Hung DT. The Drug Resistance Crisis. *Nature*. 2007;449(7157):1044-50.
- Livermore DM. Has the Era of Untreatable Infections Arrived? *J Antimicrob Chemother*. 2009;64(Suppl 1):i29-36.
- Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Bartlett JG. Bad Bugs Need Drugs: An Update on the Development Pipeline From the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. *Clin Infect Dis*. 2006;42(5):657-68.
- Arias CA, Murray BE. The Carbapenemase Threat in Enterobacteriaceae—"Here Is the Storm!". *Clin Infect Dis*. 2012;55(4):525-7.
- Gupta A, Sreenivasan P, Sivaraman S, Elangovan R. Multidrug-Resistant *Acinetobacter*: Review and Future Perspectives. *J Glob Antimicrob Resist*. 2016;6:6-12.
- Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, et al. NHSN Annual Update: Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections. *Am J Infect Control*. 2008;36(9):609-26.

25. Patel JB, Richter SS, Rasheed JK, Kitchel B. Impact of Rapid Diagnostic Tests on Clinical Outcomes in Bloodstream Infections. *J Clin Microbiol.* 2016;54(6):1444–51.
26. Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. *Clin Infect Dis.* 2016;62(10):e51–77.
27. Goff DA, File TM, Kaye KS, Kullar R, Spellberg B. Integrating Antibiotic Stewardship Into Routine Clinical Practice: A Practical Guide. *Am J Health Syst Pharm.* 2017;74(13):993–1003.
28. Nathwani D, Eckmann C, Lawson W, Stephens J, Macahilig C, Solem C. Review of 2014 Anti-Infectives by the European Medicines Agency. *J Antimicrob Chemother.* 2015;70(6):1615–20.
29. Jabeen K, Zafar A, Hasan R. Antimicrobial Resistance Trends From a Hospital and Diagnostic Facility in Lahore, Pakistan: A Five-Year Retrospective Analysis (2014–2018). *medRxiv.* 2019. doi:10.1101/19012617.
30. Khan S, Akhtar N, Akhtar K, Saeed MA, Raza S. Antimicrobial Drug Resistance Trends of Bacteria Causing Bloodstream Infections in a Diagnostic Centre in Lahore. *Pak BioMed J.* 2023;6(8):922.
31. Saleem Z, Saeed H, Hassali MA, Godman B, Asif U, Ahmad F. Antibiotic Resistance in Pakistan: A Systematic Review of the Past Decade. *SpringerMedizin.* 2021;7 Mar.
32. Asif M, Rasool MH, Ajmal M, Arshad MI, Saqalein M, Yousaf R, et al. Economic Burden of Antimicrobial Resistance on Patients in Pakistan. *Pak J Med Sci.* 2025;41(2):11893982.
33. Kathia UM, Memon Z, Memon S, Nizamani MA. Antimicrobial Resistance Patterns: Review of the Antibigram of a Surgical Unit in a Public Tertiary Care Hospital of Pakistan. *Cureus.* 2020;12(11):e11345.
34. Torumkuney D, Jamil B, Nizamuddin S, Anwar M, Hasan R. Country Data on AMR in Pakistan in the Context of Community-Acquired Respiratory Tract Infections. *J Antimicrob Chemother.* 2022;77(Suppl 1):i18–25.
35. Butt T, Afzal RK, Ahmad RN, Mahmood A. Emerging Resistance Trends in Nosocomial Pathogens in Lahore, Pakistan. *J Pak Med Assoc.* 2020;70(5):799–804.
36. Ali M, Rafi S, Qureshi AH, Gul A. Prevalence and Antimicrobial Susceptibility of Multidrug-Resistant Pathogens in Lahore Tertiary Care Hospitals. *Infect Drug Resist.* 2021;14:2193–2202.
37. Mahmood A, Butt T, Raza S. Surveillance of Antimicrobial Resistance in ESKAPE Pathogens at a Tertiary Care Hospital in Lahore. *J Coll Physicians Surg Pak.* 2022;32(8):1011–7.
38. Sarwar F, Khan MA, Anwar N, Rizwan M. Bacterial Spectrum and Antimicrobial Resistance Pattern in Hospital-Acquired Infections: A Study From Lahore. *Pak J Med Sci.* 2022;38(3):567–73.
39. Javed A, Khan Z, Hussain A, Rahman A, Akram M. Patterns of Antibiotic Resistance Among Gram-Negative Isolates in a Tertiary Care Hospital of Lahore. *J Infect Dev Ctries.* 2023;17(1):23–30.
40. Tariq S, Khan F, Aslam B, Anwar N. Antibiotic Susceptibility and Resistance Patterns of MRSA in Lahore Hospitals. *J Ayub Med Coll Abbottabad.* 2021;33(4):606–10.
41. Akram M, Shahid M, Khan AU. Etiology and Antibiotic Resistance Patterns of Community-Acquired Urinary Tract Infections in Lahore. *Ann Clin Microbiol Antimicrob.* 2022;21:12.
42. Shafqat S, Iqbal S, Raza S, Nawaz A, Ahmed T. Prevalence of ESBL and Carbapenemase Producing Enterobacteriaceae in Lahore. *J Pak Med Assoc.* 2023;73(2):321–7.
43. Riaz S, Faisal M, Zafar A, Jameel T. Antibigram of Clinical Isolates From Intensive Care Units of Lahore Hospitals. *Pak J Med Sci.* 2022;38(6):1644–50.
44. Ahmad N, Ali S, Khan AU. Molecular Characterization of Resistance Mechanisms in *Acinetobacter Baumannii* From Lahore. *Microb Drug Resist.* 2021;27(8):1092–100.
45. Rehman A, Farooq S, Shakoor S, Qazi J, Malik A. Plasmid-Mediated Colistin Resistance in *Escherichia Coli* Isolates From Lahore. *Front Microbiol.* 2022;13:823456.
46. Yousaf S, Zafar A, Anwar M, Ali M. Trends in Antibiotic Resistance Among *Pseudomonas Aeruginosa* in Lahore. *Infect Control Hosp Epidemiol.* 2023;44(2):234–40.
47. Siddiqui S, Ahmed S, Qamar FN, Iqbal S. Surveillance of Multidrug-Resistant *Klebsiella Pneumoniae* in Lahore Tertiary Care Hospitals. *BMC Infect Dis.* 2022;22:1021.
48. Bashir A, Saeed B, Raza S, Ashraf M. Prevalence of MRSA and Its Antibiotic Resistance Profile in Lahore. *Pak J Med Sci.* 2023;39(1):112–7.
49. Zahid M, Aslam B, Khurshid M, Nisar MA. Risk Factors for Multidrug-Resistant Infections in Lahore Hospitals. *J Hosp Infect.* 2022;120:45–52.